Pritesh S Karia1,2, Frederick C Morgan1, Joseph A Califano3, Chrysalyne D Schmults1. 1. Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Division of Otolaryngology-Head and Neck Surgery, University of California, San Diego, La Jolla.
Abstract
Importance: Previous studies have shown that the AJCC Cancer Staging Manual, 7th edition (AJCC 7), tumor classification for cutaneous squamous cell carcinoma (CSCC) failed to accurately stratify disease-related outcomes. The recently released 8th edition (AJCC 8) features a revised tumor classification for only head and neck CSCC (HNCSCC). Objective: To compare AJCC 7 and AJCC 8 tumor classifications for HNCSCC and to validate AJCC 8. Design, Setting, and Participants: This was a 10-year retrospective cohort study (2000-2009) at an academic tertiary care center reviewing 680 primary HNCSCC tumors in 459 patients. Main Outcomes and Measures: Primary HNCSCC tumors were reviewed for disease-related outcomes (DROs): local recurrence (LR), nodal metastasis (NM), and disease-specific death (DSD). Tumors were stratified by AJCC 7 and AJCC 8 tumor classification. Distinctiveness (outcome differences between categories), homogeneity (outcome similarity within categories), and monotonicity (outcome worsening with increasing categories) were assessed for both classifications. Results: Most of the 459 patients were white (451 [98.3%]) and male (312 [68.0%]). AJCC 8 high tumor categories (T3/T4) accounted for 121 (17.8%) of total cases but 50 of 71 DROs (70.4%) (22 of 34 of LRs [64.7%], 17 of 24 NMs [70.8%], and 11 of 13 of DSDs [84.6%]). This was a significant improvement over AJCC 7, where only 12 of 71 DROs (16.9%) (4 of 34 LRs [11.8%], 3 of 24 NMs [12.5%], and 5 of 13 DSDs [38.5%]) occurred in T3/T4 categories. However, AJCC 8 T2 and T3 were indistinct, with overlapping 95% CIs for 10-year cumulative incidences of LR, NM, and DSD. The 10-year cumulative incidence of DROs in the 119 AJCC 8 T3 cases were 19.7% (95% CI, 13.0%-29.7%) for LR, 14.1% (95% CI, 9.7%-20.7%) for NM, and 9.3% (95% CI, 6.8%-14.0% for DSD). Conclusions and Relevance: AJCC 8 demonstrates superior homogeneity and monotonicity compared with AJCC 7. It now may be possible for AJCC 8 HNCSCC T2, T3, and T4 cases to be recorded and tracked by tumor registries because they represented a 23.1% subset in this study, which includes nearly all poor outcomes (85.9%). Further work is needed to validate AJCC 8 with population-level data and to compare AJCC 8 performance against alternative tumor classifications.
Importance: Previous studies have shown that the AJCC Cancer Staging Manual, 7th edition (AJCC 7), tumor classification for cutaneous squamous cell carcinoma (CSCC) failed to accurately stratify disease-related outcomes. The recently released 8th edition (AJCC 8) features a revised tumor classification for only head and neck CSCC (HNCSCC). Objective: To compare AJCC 7 and AJCC 8 tumor classifications for HNCSCC and to validate AJCC 8. Design, Setting, and Participants: This was a 10-year retrospective cohort study (2000-2009) at an academic tertiary care center reviewing 680 primary HNCSCC tumors in 459 patients. Main Outcomes and Measures: Primary HNCSCC tumors were reviewed for disease-related outcomes (DROs): local recurrence (LR), nodal metastasis (NM), and disease-specific death (DSD). Tumors were stratified by AJCC 7 and AJCC 8 tumor classification. Distinctiveness (outcome differences between categories), homogeneity (outcome similarity within categories), and monotonicity (outcome worsening with increasing categories) were assessed for both classifications. Results: Most of the 459 patients were white (451 [98.3%]) and male (312 [68.0%]). AJCC 8 high tumor categories (T3/T4) accounted for 121 (17.8%) of total cases but 50 of 71 DROs (70.4%) (22 of 34 of LRs [64.7%], 17 of 24 NMs [70.8%], and 11 of 13 of DSDs [84.6%]). This was a significant improvement over AJCC 7, where only 12 of 71 DROs (16.9%) (4 of 34 LRs [11.8%], 3 of 24 NMs [12.5%], and 5 of 13 DSDs [38.5%]) occurred in T3/T4 categories. However, AJCC 8 T2 and T3 were indistinct, with overlapping 95% CIs for 10-year cumulative incidences of LR, NM, and DSD. The 10-year cumulative incidence of DROs in the 119 AJCC 8 T3 cases were 19.7% (95% CI, 13.0%-29.7%) for LR, 14.1% (95% CI, 9.7%-20.7%) for NM, and 9.3% (95% CI, 6.8%-14.0% for DSD). Conclusions and Relevance: AJCC 8 demonstrates superior homogeneity and monotonicity compared with AJCC 7. It now may be possible for AJCC 8 HNCSCC T2, T3, and T4 cases to be recorded and tracked by tumor registries because they represented a 23.1% subset in this study, which includes nearly all poor outcomes (85.9%). Further work is needed to validate AJCC 8 with population-level data and to compare AJCC 8 performance against alternative tumor classifications.
Authors: Elliot A Asare; Mary Kay Washington; Donna M Gress; Jeffrey E Gershenwald; Frederick L Greene Journal: CA Cancer J Clin Date: 2015-05-07 Impact factor: 508.702
Authors: Sharifeh Farasat; Siegrid S Yu; Victor A Neel; Kishwer S Nehal; Thomas Lardaro; Martin C Mihm; David R Byrd; Charles M Balch; Joseph A Califano; Alice Y Chuang; William H Sharfman; Jatin P Shah; Paul Nghiem; Clark C Otley; Anthony P Tufaro; Timothy M Johnson; Arthur J Sober; Nanette J Liégeois Journal: J Am Acad Dermatol Date: 2011-01-20 Impact factor: 11.527
Authors: Anokhi Jambusaria-Pahlajani; Peter A Kanetsky; Pritesh S Karia; Wei-Ting Hwang; Joel M Gelfand; Faith M Whalen; Rosalie Elenitsas; Xiaowei Xu; Chrysalyne D Schmults Journal: JAMA Dermatol Date: 2013-04 Impact factor: 10.282
Authors: Joi B Carter; Matthew M Johnson; Tiffany L Chua; Pritesh S Karia; Chrysalyne D Schmults Journal: JAMA Dermatol Date: 2013-01 Impact factor: 10.282
Authors: Pritesh S Karia; Anokhi Jambusaria-Pahlajani; David P Harrington; George F Murphy; Abrar A Qureshi; Chrysalyne D Schmults Journal: J Clin Oncol Date: 2013-12-23 Impact factor: 44.544
Authors: A Tejera-Vaquerizo; J Cañueto; A Toll; J Santos-Juanes; A Jaka; C Ferrandiz; O Sanmartín; S Ribero; D Moreno-Ramírez; F Almazán; M J Fuente; S Podlipnik; E Nagore Journal: Actas Dermosifiliogr Date: 2020-09-20
Authors: J Claveau; J Archambault; D S Ernst; C Giacomantonio; J J Limacher; C Murray; F Parent; D Zloty Journal: Curr Oncol Date: 2020-08-01 Impact factor: 3.677
Authors: Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day Journal: Ann Surg Oncol Date: 2021-06-30 Impact factor: 5.344
Authors: Priscilla J Tanamal; Calvin X Geng; Rajiv I Nijhawan; Erin Wynings; Sanjana Balachandra; Larry L Myers; Brittny N Tillman; Andrew T Day Journal: Eur Arch Otorhinolaryngol Date: 2021-05-06 Impact factor: 2.503
Authors: Sarah T Arron; Ashley Wysong; Mary A Hall; Christine N Bailey; Kyle R Covington; Sarah J Kurley; Matthew S Goldberg; Julia M Kasprzak; Ally-Khan Somani; Sherrif F Ibrahim; David G Brodland; Nathan J Cleaver; Ian A Maher; Yang Xia; Shlomo A Koyfman; Jason G Newman Journal: Laryngoscope Investig Otolaryngol Date: 2022-01-06
Authors: Aaron S Farberg; Alison L Fitzgerald; Sherrif F Ibrahim; Stan N Tolkachjov; Teo Soleymani; Leah M Douglas; Sarah J Kurley; Sarah T Arron Journal: Dermatol Ther (Heidelb) Date: 2022-01-07
Authors: A Tejera-Vaquerizo; J Cañueto; A Toll; J Santos-Juanes; A Jaka; C Ferrandiz-Pulido; O Sanmartín; S Ribero; D Moreno-Ramírez; F Almazán; M J Fuente; S Podlipnik; E Nagore Journal: Actas Dermosifiliogr (Engl Ed) Date: 2020-05-11